GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioMarin Pharmaceutical
BioMarin Pharmaceutical specializes in treating rare genetic diseases. Its stock price is driven by successes in developing and commercializing orphan drugs. Its chart is a history of scientific breakthroughs that can dramatically change patients' lives and generate huge revenues.
Share prices of companies in the market segment - Specialized pharma
BioMarin specializes in the treatment of rare genetic diseases. We classify it as a specialty pharmaceutical company. The chart below shows the overall dynamics of this sector, where value is determined by scientific breakthroughs and the commercialization of orphan drugs.
Broad Market Index - GURU.Markets
BioMarin Pharmaceutical is a biotech company focused on developing drugs to treat rare genetic diseases. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare this biotech player's stock to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BMRN - Daily change in the company's share price BioMarin Pharmaceutical
The daily price change for BioMarin, a leader in rare disease treatments, is a measure of its volatility and response to new drug approvals. While the chart of these fluctuations isn't spectacular, it's an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
BioMarin Pharmaceutical Inc. is a leader in treating rare genetic diseases. This chart highlights the high volatility of the biotech sector. Comparing it to BMRN's performance helps us understand how sensitive its orphan drug portfolio makes it to broader industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
BioMarin is a leader in developing drugs to treat rare genetic diseases. Biotech focused on rare diseases is a volatile niche. The chart below shows the average fluctuations in this sector, allowing you to assess the risks and potential of BioMarin shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioMarin Pharmaceutical
BioMarin is a leading biotech company specializing in the treatment of rare genetic diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough products.
Annual dynamics of market capitalization of the market segment - Specialized pharma
BioMarin Pharmaceutical Inc. is a biotech company focused exclusively on treating rare genetic diseases. Its expertise in this complex niche gives it a strong market position and significant pricing power. The chart below shows how its orphan drug portfolio impacts its performance compared to Big Pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioMarin Pharmaceutical is a biotechnology company specializing in the treatment of rare (orphan) diseases. Its business model, based on drugs for small patient groups at high prices, is resilient to economic cycles. Share price performance is driven by scientific advances and regulatory approvals.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioMarin Pharmaceutical
The market capitalization of BioMarin, a biotech company focused on rare genetic diseases, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its drugs and, more importantly, news about clinical trials and approvals of new treatments.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
This chart reflects the dynamics of the biotech sector, particularly in the rare disease segment, where BioMarin is a leader. Its movements demonstrate how the company, with its portfolio of approved drugs, continues to invest in innovative therapies, including gene therapies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioMarin Pharmaceutical specializes in drugs for the treatment of rare (orphan) genetic diseases. Its business is independent of economic cycles. Against the backdrop of general market trends shown in the chart, BioMarin's performance is determined by successes in clinical trials and the launch of new drugs, which can command very high prices due to their unique nature.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioMarin Pharmaceutical
BioMarin Pharmaceutical specializes in the treatment of rare genetic diseases. The company's shares exhibit high weekly volatility, responding to the publication of clinical trial data, regulatory decisions (FDA), and news of the commercial success of its drugs.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
BioMarin is a biotech company focused on rare diseases. Comparing its weekly performance to the biotech sector can be misleading. The chart shows how news about its key drugs gives its shares a life of their own, often ignoring broader industry trends and investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioMarin, a biotech company, lives in its own world, far removed from macroeconomic news. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
BMRN - Market capitalization of the company BioMarin Pharmaceutical
BioMarin Pharmaceutical's market capitalization is a story of hope and disappointment in the treatment of rare genetic diseases. The company's stock price is sensitive to clinical trial results and regulatory decisions regarding its blockbuster drugs. Every move reflects investors' assessment of the scientific breakthrough and commercial potential of orphan pharmaceuticals.
BMRN - Share of the company's market capitalization BioMarin Pharmaceutical within the market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. The company's market share reflects its leadership and expertise in orphan diseases. The chart below shows BioMarin's market share, where success depends on unique scientific developments rather than mass sales.
Market capitalization of the market segment - Specialized pharma
BioMarin develops drugs for rare (orphan) genetic diseases. This is a niche but high-margin segment of the pharmaceutical industry. The chart below shows the overall market capitalization of the biotech sector. It reflects investors' willingness to fund expensive research in the hopes of a breakthrough that could change patients' lives.
Market capitalization of all companies included in a broad market index - GURU.Markets
The BioMarin line on the chart represents hope for patients with rare diseases. The company develops drugs for orphan diseases where there is no competition. Its market capitalization reflects its success in this challenging niche. The chart demonstrates how highly specialized science can create enormous value, changing people's lives.
Book value capitalization of the company, segment and market as a whole
BMRN - Book value capitalization of the company BioMarin Pharmaceutical
BioMarin Pharmaceutical's capital consists of patents for orphan drugs, R&D laboratories, and manufacturing facilities for their production. Its book value reflects the scientific and material foundation for treating rare diseases. The chart below shows how the successful commercialization of unique drugs and investments in research have grown the company's capital base.
BMRN - Share of the company's book capitalization BioMarin Pharmaceutical within the market segment - Specialized pharma
BioMarin Pharmaceutical develops drugs for rare diseases, which requires a unique scientific and manufacturing base. Its assets include advanced laboratories and specialized biopharmaceutical manufacturing facilities. The chart shows the company's share of the complex and expensive physical infrastructure of this niche sector.
Market segment balance sheet capitalization - Specialized pharma
BioMarin Pharmaceutical, which develops drugs for rare diseases, requires significant R&D investment and owns manufacturing facilities. It's a capital-intensive business. The BCap_Seg chart for the biotech sector shows that success in this industry requires a strong scientific and manufacturing base.
Book value of all companies included in the broad market index - GURU.Markets
BioMarin's assets are not giant factories, but high-tech laboratories and production facilities for developing drugs for rare genetic diseases. The company's balance sheet reflects the value of its intellectual property and unique equipment. The chart below illustrates the scale of these science-intensive assets in the pharmaceutical industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioMarin Pharmaceutical
BioMarin's balance sheet consists of its laboratories and factories. But the market pays a colossal premium for its unique expertise in treating rare genetic diseases and its portfolio of approved blockbuster drugs. The chart is an assessment of its scientific leadership and ability to save lives while turning that into profit.
Market to book capitalization ratio in a market segment - Specialized pharma
BioMarin Pharmaceutical specializes in drugs for rare diseases. The company's value is determined by its unique patents and drugs, which are highly priced due to the lack of comparable products. The chart reflects the immense value of its intellectual property compared to its physical assets.
Market to book capitalization ratio for the market as a whole
BioMarin Pharmaceutical develops drugs for rare genetic diseases. The company's value lies in its unique patents and scientific developments. This leads to its market capitalization significantly exceeding its book value, reflecting investor hopes for new breakthrough drugs.
Debts of the company, segment and market as a whole
BMRN - Company debts BioMarin Pharmaceutical
BioMarin Pharmaceutical, a company focused on rare genetic diseases, uses debt to fund expensive research and bring orphan drugs to market. Developing such drugs requires huge investments and high risk. This chart shows how the company leverages debt to bring its life-saving innovations to patients.
Market segment debts - Specialized pharma
BioMarin Pharmaceutical develops drugs for rare genetic diseases. This niche carries high scientific risk but also offers enormous potential. Its debt policy is a bet on the success of future drugs. This chart shows how aggressively the company finances its expensive research, borrowing heavily in anticipation of a breakthrough.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioMarin Pharmaceutical
BioMarin Pharmaceutical develops drugs to treat rare diseases, which entails high research costs. This chart shows how the company finances its research and development activities. It provides insight into its financial independence: whether expenses are covered by revenue from existing drugs or whether the company is forced to take on significant debt.
Market segment debt to market segment book capitalization - Specialized pharma
BioMarin Pharmaceutical develops drugs for rare (orphan) diseases. This entails high R&D costs and risks in clinical trials. The chart shows how the company's debt burden, required to fund research, compares to the overall financial capacity and risks of the biotech industry.
Debt to book value of all companies in the market
BioMarin Pharmaceutical, a developer of drugs for rare diseases, invests heavily in R&D. This chart places these risky investments in a broader economic context, comparing the company's debt to the total capitalization of the entire stock market.
P/E of the company, segment and market as a whole
P/E - BioMarin Pharmaceutical
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. This chart shows how the market perceives its success. This indicator's performance is highly dependent on clinical trial results, regulatory approvals of new drugs, and their commercial potential, as is typical for the biotech sector.
P/E of the market segment - Specialized pharma
BioMarin specializes in drugs for rare diseases, which allows it to command high prices and protect itself from competition. This chart shows the average valuation for the biotech sector. Comparisons with this valuation help us understand whether BioMarin is earning a premium for its successful niche strategy and approved drug portfolio.
P/E of the market as a whole
BioMarin Pharmaceutical develops drugs to treat rare (orphan) diseases. This niche has a high barrier to entry and unique dynamics. This chart reflects general market sentiment. BioMarin's valuation, however, depends more on clinical trial results and regulatory decisions than on the overall economic climate, creating its own investment story.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioMarin Pharmaceutical
BioMarin Pharmaceutical develops drugs to treat rare (orphan) genetic diseases. This chart shows how the market values its pipeline of approved drugs and the potential for future developments. The price action reflects investor confidence in its competitive pricing and demand for its unique therapies.
%20P%2FE%20BioMarin%20Pharmaceutical&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioMarin-Pharmaceutical&v=1772648689489 "Chart of the company's future (projected) P/E BioMarin Pharmaceutical")
Future (projected) P/E of the market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes drugs to treat rare (orphan) genetic diseases. This chart shows the average profitability expectations for the sector. It provides insight into how highly the market values BioMarin's unique drug portfolio and its ability to command high prices for life-saving medications.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772648689540 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
BioMarin Pharmaceutical specializes in developing drugs to treat rare (orphan) diseases caused by genetic disorders. This chart reflects collective market expectations. For a biotech company focused on unique niches, it helps assess how investors view the healthcare sector and whether they are willing to pay for breakthrough, but expensive, drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648689567 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioMarin Pharmaceutical
BioMarin Pharmaceutical develops and commercializes drugs for the treatment of rare (orphan) diseases. The bottom line, presented here, depends on the success of a small number of highly specialized and expensive drugs. The chart illustrates how innovations in niche medical areas can generate significant financial value for the company.
Profit of companies in the market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. The company's business model is based on high-cost therapies for small patient populations. This chart shows the overall profitability of the orphan drug sector, where BioMarin's scientific breakthroughs create new markets and generate significant revenue.
Overall market profit
BioMarin Pharmaceutical develops drugs to treat rare (orphan) genetic diseases. Demand for its medications is highly inelastic, but the high cost of treatment makes the company dependent on the solvency of healthcare systems. Overall economic health, reflected in this chart, impacts healthcare budgets and their ability to cover expensive innovative treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company focused on developing drugs for the treatment of rare (orphan) diseases. The profit forecast presented here depends on the market success of its drugs and the results of clinical trials of its new developments. Analysts assess the potential of the company's portfolio in a niche where competition is lower and drug prices are high.
%20profit%20of%20the%20company%20BioMarin%20Pharmaceutical&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioMarin-Pharmaceutical&v=1772648689584 "Graph of future (projected) profit of the company BioMarin Pharmaceutical")
Future (predicted) profit of companies in the market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. This is a high-risk but potentially highly profitable segment of biotech. This chart shows the profit forecast for specialty pharmaceuticals, helping to assess the scientific and commercial potential of BioMarin's drug portfolio relative to the industry as a whole.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772648689609 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
BioMarin Pharmaceutical develops drugs to treat rare (orphan) diseases. Demand for its drugs is not as dependent on economic cycles as for other companies, but the overall health of healthcare systems and their funding, which are influenced by the economic climate (shown in this chart), play a significant role in access to treatment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648689619 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioMarin Pharmaceutical
BioMarin Pharmaceutical develops drugs to treat rare genetic diseases. This chart shows how investors value its revenue. Its high sales valuation reflects the uniqueness of its drugs, their high prices, and patient loyalty, which creates a predictable and secure cash flow.
P/S market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. The company's revenue depends on the success of its orphan drug candidates, which are often highly priced and face limited competition. This chart provides an insight into how investors value BioMarin's unique portfolio compared to other pharmaceutical companies.
P/S of the market as a whole
BioMarin Pharmaceutical develops and commercializes innovative drugs for the treatment of rare (orphan) genetic diseases. It's a high-risk, but potentially highly profitable, business. This chart helps understand how the market values biotech companies whose revenue depends on the success of a few key drugs, compared to more diversified industries.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioMarin Pharmaceutical
BioMarin Pharmaceutical develops drugs to treat rare genetic diseases. This chart shows how the market values the company relative to its future sales. It reflects investors' high expectations for existing drugs and potential blockbusters in development that could dramatically change patients' lives.
%20P%2FS%20BioMarin%20Pharmaceutical&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioMarin-Pharmaceutical&v=1772648689657 "The graph of the company's future (projected) P/S BioMarin Pharmaceutical")
Future (projected) P/S of the market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. The company holds a leading position in its narrow but vital niche. This chart shows the market premium the company is willing to impose on future sales of its unique drugs compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772648689665 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
BioMarin Pharmaceutical develops drugs to treat rare (orphan) diseases. The company's success depends on clinical trial results and regulatory approvals, not on general economic trends. This graph is not a direct driver for BMRN. Demand for its drugs is determined by medical needs and is inelastic to economic conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648689708 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioMarin Pharmaceutical
This chart illustrates advances in rare disease treatment. For BioMarin Pharmaceutical, a biotech company, it reflects sales volumes of highly specialized and expensive drugs. This trend is directly related to demand for medications for patients with genetic diseases who have few alternative treatment options.
Sales of companies in the market segment - Specialized pharma
BioMarin Pharmaceutical develops and commercializes drugs to treat rare genetic diseases. The company's success depends on regulatory approval of its innovative therapies and their implementation in clinical practice. This chart illustrates how scientific breakthroughs and the high cost of orphan drugs shape the financial flows of BioMarin and the entire biotech sector.
Overall market sales
BioMarin Pharmaceutical develops drugs for rare genetic diseases. The company's success depends on scientific breakthroughs and the ability to commercialize unique treatments. It is an example of a business driven by innovation in healthcare—a sector that makes up a significant and growing portion of the economy, as reflected in this broad chart.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioMarin Pharmaceutical
BioMarin Pharmaceutical develops innovative treatments for rare genetic diseases. The company's future sales depend on the approval and successful launch of new drugs, which often come at a very high price. This chart reflects analysts' forecasts for the commercial potential of the company's unique development pipeline.
%20sales%20of%20the%20company%20BioMarin%20Pharmaceutical&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioMarin-Pharmaceutical&v=1772648689810 "Schedule of future (projected) sales of the company BioMarin Pharmaceutical")
Future (projected) sales of companies in the market segment - Specialized pharma
BioMarin Pharmaceutical develops drugs for rare (orphan) genetic diseases. The outlook for the specialty pharmaceutical sector reflects scientific progress and pricing policy. This chart shows how much the market is willing to pay for innovative treatments that transform the lives of patients with rare diagnoses.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772648689826 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
BioMarin Pharmaceutical develops drugs to treat rare genetic diseases. Demand for its medications is inelastic and unaffected by short-term economic fluctuations. These medications are vital for patients. However, the overall economic situation, as reflected here, may impact the ability of healthcare systems and insurance companies to reimburse the cost of expensive treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648689830 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioMarin Pharmaceutical
For BioMarin Pharmaceutical, which specializes in treating rare genetic diseases, this chart reflects the uniqueness of its business model. Its high profitability is driven by the development and sale of orphan drugs at premium prices, which allows it to cover significant R&D costs and bring life-saving, albeit niche, medications to market.
Market segment marginality - Specialized pharma
BioMarin Pharmaceutical develops and commercializes drugs for the treatment of rare (orphan) genetic diseases. This chart shows the average profitability in the biotech sector. Focusing on niche markets with high unmet needs and premium pricing for its unique drugs allows the company to achieve very high profitability.
Market marginality as a whole
BioMarin Pharmaceutical is a biotechnology company focused on developing drugs for the treatment of rare (orphan) diseases. This chart shows average revenue. It illustrates BioMarin's business model, where drugs for a small number of patients can be very expensive, yet provide high profitability if clinical trials are successful.
Employees in the company, segment and market as a whole
Number of employees in the company BioMarin Pharmaceutical
BioMarin Pharmaceutical develops and commercializes innovative treatments for rare genetic diseases. Its team consists of highly qualified scientists and specialists. The growth visible in this graph is directly related to the advancement of drugs through clinical trials and the expansion of its commercial infrastructure to bring new drugs to market.
Share of the company's employees BioMarin Pharmaceutical within the market segment - Specialized pharma
BioMarin Pharmaceutical is a biotechnology company focused on the development and commercialization of innovative treatments for rare (orphan) genetic diseases. This indicator reflects its scientific specialization and demonstrates the significant share of genetic scientists and physicians BioMarin attracts in this narrow and complex field of medicine.
Number of employees in the market segment - Specialized pharma
BioMarin Pharmaceutical develops drugs to treat rare (orphan) diseases. This chart shows the employment dynamics in this highly specialized field of biotechnology. The growth in the number of scientists and clinicians here is driven by scientific breakthroughs and the humanitarian mission of creating treatments for patients with previously incurable genetic diseases.
Number of employees in the market as a whole
BioMarin Pharmaceutical develops drugs to treat rare genetic diseases. Demand for its high-priced medications is less dependent on economic cycles, but the healthcare system as a whole is. Stable employment, as seen in this graph, provides more people with private and public insurance, improving patient access to treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioMarin Pharmaceutical (BMRN)
BioMarin is a leading biotech company focused on rare (orphan) diseases. This chart shows how scientific expertise creates enormous value. The high market capitalization per employee demonstrates that its team of scientists is capable of creating unique drugs that, despite a small market, can command a very high price.
%20of%20the%20company%20BioMarin%20Pharmaceutical%20(BMRN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioMarin-Pharmaceutical-BMRN&v=1772648689983 "Chart of market capitalization per employee (in thousands of dollars) of the company BioMarin Pharmaceutical (BMRN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
BioMarin Pharmaceutical focuses on developing and commercializing treatments for rare (orphan) diseases, often genetic. It's a high-risk but potentially high-margin biotech business. This chart shows the industry average cost per employee. It helps assess how the market values BioMarin's scientific portfolio and its ability to bring unique drugs to market.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772648689988 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
BioMarin Pharmaceutical develops and commercializes drugs for the treatment of rare (orphan) diseases. These drugs are very expensive, allowing the company to remain profitable even with a small patient base. This graph reflects the high employee valuation, as scientific breakthroughs in this niche can lead to the creation of unique and very expensive drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648689989 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical is a biotech company specializing in orphan diseases (rare genetic disorders). Their drugs are very expensive, but they target small patient groups. This ratio is often high. It reflects how the team of scientists and specialists generates significant profit per employee due to the high price and vital importance of their unique drugs.
%20Chart%20BioMarin%20Pharmaceutical%20(BMRN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioMarin-Pharmaceutical-BMRN&v=1772648689998 "Company Profit Per Employee (in thousands of dollars) Chart BioMarin Pharmaceutical (BMRN)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
BioMarin is a leader in orphan drug R&D (for rare diseases). This chart sets the benchmark for specialty pharma. The average profit per employee in this sector is astronomical. It's a "blockbuster business." A single successful patent for a drug for a rare disease (with a very high price tag) can generate billions.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772648690024 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
BioMarin Pharmaceutical develops drugs to treat rare (orphan) diseases. Prices for such drugs can be extremely high due to the complexity of development and the small patient population. This chart illustrates the economics of biotech, where a single successful drug can generate enormous revenue, providing phenomenal returns per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648690034 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical develops drugs for rare genetic diseases. This chart demonstrates the commercial viability of its unique drugs. Its very high revenue per employee is a result of its high pricing and the lack of competition for its orphan drugs. This is an indicator of not production efficiency, but rather of long-term investment in research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioMarin-Pharmaceutical-BMRN&v=1772648690048 "Sales chart per company employee BioMarin Pharmaceutical (BMRN)")
Sales per employee in the market segment - Specialized pharma
BioMarin Pharmaceutical focuses on developing drugs for rare (orphan) diseases, a niche biotech segment with very high drug prices. This metric reflects how effectively their team of scientists and sales professionals monetizes their unique portfolio. A high score indicates the success of their R&D strategy.
Sales per employee for the market as a whole
BioMarin Pharmaceutical is a biotechnology company specializing in the development and commercialization of treatments for rare (orphan) genetic diseases. It's a research-intensive business. This graph shows how much revenue each employee generates. High numbers reflect the company's ability to command high prices for its unique, life-saving drugs, which justifies its enormous R&D expenditures.
Short shares by company, segment and market as a whole
Shares shorted by company BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical specializes in developing drugs for rare (orphan) genetic diseases. This allows the company to set very high prices for its drugs. This chart indicates bearish sentiment. Bears may be concerned that the company's new drugs will not be approved, that existing ones will face competition, or that regulators will put pressure on prices.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioMarin-Pharmaceutical-BMRN&v=1772648690119 "Short Shares Chart for the Company BioMarin Pharmaceutical (BMRN)")
Shares shorted by market segment - Specialized pharma
BioMarin Pharmaceutical focuses on rare (orphan) diseases, developing high-cost gene and enzyme therapies. This chart shows overall short positions across the biotech sector. High short positions in the industry often signal general investor fears of clinical trial failures or, more importantly, regulatory pressure on orphan drug prices.
Shares shorted by the overall market
BioMarin (BMRN) is a biotech company focused on treating rare ("orphan") genetic diseases. This chart shows the overall level of fear. When pessimism rises, BMRN is a "fortress." Their drugs cost hundreds of thousands of dollars and are vital for patients. Demand for them is completely inelastic and unaffected by recessions.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioMarin Pharmaceutical (BMRN)
BioMarin is a biotech leader in treating ultra-rare genetic diseases. This chart measures the response to binary events. Successful Phase 3 data for their new gene therapy (which could cost $3 million) could trigger explosive growth and euphoria, pushing this chart above 70. A trial failure would send this chart below 30.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioMarin-Pharmaceutical-BMRN&v=1772648690160 "RSI 14 indicator chart for the company's stock BioMarin Pharmaceutical (BMRN)")
RSI 14 Market Segment - Specialized pharma
BioMarin (BMRN) is a biotech pioneer focused exclusively on "ultra-rare" diseases. They develop blockbuster drugs for very small patient populations. This chart shows the overall sentiment in the biotech sector. It helps us understand: is BMRN oversold due to R&D issues or is there a general cooling off in the sector?
RSI 14 for the overall market
BioMarin Pharmaceutical (BMRN) is a biotech company specializing in the treatment of rare (orphan) diseases. Their drugs are very expensive and have few competitors. This indicator of market fear is still important. Although demand for their drugs is stable, during periods of panic, investors may fear increased government pressure on drug prices, which impacts the entire sector.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BMRN (BioMarin Pharmaceutical)
BioMarin is a biotech company specializing in developing drugs for rare (orphan) genetic diseases, often affecting children. Their business is based on extremely high drug prices. This chart shows the average 12-month target from analysts. It reflects their forecasts for sales of existing drugs and the success of gene therapy launches.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BMRN-BioMarin-Pharmaceutical&v=1772648690201 "A chart showing analyst consensus forecasts for the expected stock price. BMRN (BioMarin Pharmaceutical)")
The difference between the consensus estimate and the actual stock price BMRN (BioMarin Pharmaceutical)
BioMarin is a biotech company specializing in the treatment of ultra-rare genetic diseases for which there are often no other available treatments. Their drugs are very expensive. This chart shows how much analysts believe in their R&D pipeline and their ability to commercialize this niche therapy. It reflects the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BMRN-BioMarin-Pharmaceutical&v=1772648690238 "A chart showing the difference between the consensus forecast and the actual stock price. BMRN (BioMarin Pharmaceutical)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
BioMarin is a biotech company specializing in developing drugs for "ultra-rare" genetic diseases. It's a business with high prices and small patient populations. This chart shows analysts' general expectations for the specialty pharmaceutical sector. It reflects whether experts believe in the success of R&D in rare diseases.
Analysts' consensus forecast for the overall market share price
BioMarin Pharmaceutical is a biotech company focused on rare (orphan) genetic diseases. They produce extremely expensive drugs. Market expectations, as shown in this chart, impact budgets. During a recession (pessimism), payers (governments, insurers) begin to put greater pressure on prices, even for life-saving orphan drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioMarin Pharmaceutical
BioMarin is a biotech company focused exclusively on treating ultra-rare genetic diseases (orphan drugs). Their drugs are very expensive, but they serve small patient populations. This chart is an assessment of their unique scientific niche. It reflects their ability to secure approvals for new treatments and justify their high prices.
AKIMA Market Segment Index - Specialized pharma
BioMarin is a pioneer in ultra-rare genetic diseases; the company dominates enzyme therapy and is a leader in gene therapy (for hemophilia). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: to what extent does BioMarin's technological leadership in gene therapy differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
BioMarin is a biotech company focused on developing and commercializing drugs for ultra-rare genetic diseases. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to broader economic trends that influence investor risk appetite.
